Anika adds to gains following FDA approval of Monovisc


Anika Therapeutics (ANIK) surges 41% to $48.67 following the FDA's approval of the company's Monovisc single injection for pain caused by osteoarthritis of the knee.

The authorization must feel pretty sweet for Anika - it first applied for approval over four years ago.

Summer Street has hiked its price target to $60 a share from a prior PT of $47.

"We believe this product will be competitive in a market that is becoming more focused on single-shot injections," Summer Street says.

There are 27M people in the U.S. who suffer from osteoarthritis, which occurs when cartilage breaks down in joints, causing pain and stiffness as bones rub together.

Sanofi (SNY +0.1%) and Zimmer (ZMH +0.4%) sell rival products.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs